Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

PHASE 2B CLINICAL TRIAL APPLICATION SUBMISSION OF CORE PRODUCT VORTOSIRAN FOR VENOUS THROMBOEMBOLISM

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide shareholders of the Company (the "**Shareholders**") and potential investors with an update on the Group's research and development progress.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce the successful submission of the phase 2b clinical trial application (CTA) for the Company's core product vortosiran (RBD4059) for prevention of venous thromboembolism (VTE) at the European Medicines Agency (EMA). This study is a part of the Company's clinical program encompassing multiple planned phase 2b studies across multiple thromboembolic cardiovascular indications.

VTE remains a major global health burden, affecting an estimated ten million people worldwide each year and representing a leading cause of cardiovascular morbidity and mortality, with a significant proportion of patients being undertreated or discontinuing therapy due to bleeding concerns associated with current anticoagulants.

Vortosiran, a small interfering RNA (siRNA) drug for the treatment of thrombotic diseases, is designed to achieve selective and durable suppression of factor XI (FXI), thereby blocking the FXI-mediated coagulation pathway and inhibiting FXI clotting activity, with the potential to provide robust thromboembolic protection while reducing bleeding risk, and addressing a critical unmet medical need to improve benefit-risk balance compared to current anticoagulant therapies.

Vortosiran is the most advanced siRNA-based FXI inhibitor currently in clinical development, and its phase 2a clinical trial in coronary artery disease (CAD) in Europe has been completed as of the date of this announcement, and its phase 2b CTA in atrial fibrillation (AF) has been submitted at EMA in April 2026.

Vortosiran may not ultimately be successfully developed and commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, May 11, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.